The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy.
 
Li-Tzong Chen
Honoraria - PharmaEngine
Consulting or Advisory Role - PharmaEngine
Other Relationship - Merrimack
 
Jens T Siveke
Consulting or Advisory Role - Merrimack
 
Andrea Wang-Gillam
Honoraria - Merrimack; Pfizer
Consulting or Advisory Role - Merrimack; pfizer
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); CTI (Inst); EMD Serono (Inst); Halozyme (Inst); Merrimack (Inst); Newlink Genetics (Inst); OncoMed (Inst); pfizer (Inst); Precision Therapeutics (Inst); Prometheus (Inst)
Travel, Accommodations, Expenses - Axis Pharma
 
Richard Hubner
No Relationships to Disclose
 
Shubham Pant
Consulting or Advisory Role - Celgene; Halozyme
 
Tomislav Dragovich
Employment - Taiho Pharmaceutical (I)
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Merrimack (Inst)
 
Vincent M. Chung
Consulting or Advisory Role - Celgene; Perthera
Speakers' Bureau - Celgene
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Celgene
 
David Z. Chang
No Relationships to Disclose
 
Paul J. Ross
Honoraria - Celgene; Roche/Genentech; Sanofi; Sirtex Medical
Consulting or Advisory Role - Baxter; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Merck Serono; Roche/Genentech; Sirtex Medical
Research Funding - Sanofi
Patents, Royalties, Other Intellectual Property - Amgen; Bayer; Celgene; Merck Serono; Sanofi
 
Prasad Cooray
No Relationships to Disclose
 
Niall C. Tebbutt
No Relationships to Disclose
 
Fabio A. Franke
No Relationships to Disclose
 
Bruce Belanger
Employment - Merrimack
 
Navreet Dhindsa
Employment - Merrimack
Patents, Royalties, Other Intellectual Property - Merrimack
 
Floris de Jong
Employment - Baxalta; Merck Serono; Pharmacyclics
Stock and Other Ownership Interests - Amgen; Baxalta; Pharmacyclics
 
Khalid Mamlouk
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
Travel, Accommodations, Expenses - Merrimack
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Cell Therapeutics; CerRx; EmergingMed; McKesson; Medtronic; SynDevRx
Honoraria - Celgene; Cerulean Pharma; Genentech
Consulting or Advisory Role - AADi; Alethia Biotherapeutics; Alpha Cancer Technologies; Aptose Biosciences; Arsia Therapeutics; Arvinas; Bellicum Pharmaceuticals; BiolineRx; Biological Dynamics; Bionomics; Bristol-Myers Squibb; CanBas; Cavion; Cerulean Pharma; CV6 Therapeutics ; CytomX Therapeutics; CytRx Corporation; dalian wanchun biotechnology; Deciphera; DNAtrix; EMD Serono; Esperance Pharmaceuticals; Evelo Therapeutics; Five Prime Therapeutics; Formula Pharmaceuticals; Fujifilm; Gilead Sciences; HealthCare Pharmaceuticals; Histogen; Horizon Discovery; Horizon Pharma; Idera; Ignyta; Imaging Endpoints; Immodulon Therapeutics; Inform Genomics; Innate Pharma; Insys Therapeutics; Intezyne Technologies; Kalos Therapeutics; Kinex; Kura Oncology; Lantern Pharma; Lilly; Lixte Biotechnology; MBC Pharma; Medelis; Medical Prognosis Institute; Merus; miRNA Therapeutics; Nucana; Oncolytics; Oncolyze; Pain Therapeutics; Pain Therapeutics; Pfizer; Pharmacyclics; Pharmamab; Phosplatin Therapeutics; Progen; RenovoRx; Samsung; Samumed; Senhwa Biosciences; SOTIO; Strategia Therapeutics; Sun Biopharma; Superlab Far East; Synergene; Systems Imagination; TD2; Theravance; Tolero Pharmaceuticals; Toray Industries; Trovagene; Ventana Medical Systems
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Aduro Biotech (Inst); Agios (Inst); ArQule (Inst); Baxalta (Inst); Biomarin (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); ESSA (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); miRNA Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Samumed (Inst); Strategia (Inst); Trovagene (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
Travel, Accommodations, Expenses - FORMA Therapeutics; Merrimack